6 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 10 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Active not recruiting 1, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Angelman Syndrome: new trials by email Literature Review of Angelman Syndrome trials Research Report on Angelman Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome MVX-220 - Angelman Syndrome | Phase 1 / Phase 2 | Recruiting | MavriX Bio, LLC | 12 | 2025-10-29 | 2026-07-24 |
| A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) No intervention, GTX-102 - Angelman Syndrome | Phase 2 | Terminated | Ultragenyx Pharmaceutical Inc | 55 | 2025-10-13 | 2026-11-03 |
| A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. Alogabat - Angelman Syndrome | Phase 2 | Completed | Hoffmann-La Roche | 48 | 2023-07-27 | 2025-12-04 |
| An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome NNZ-2591 - Angelman Syndrome | Phase 2 | Completed | Neuren Pharmaceuticals Limited | 17 | 2022-07-12 | 2025-01-31 |
| HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome ION582 - Angelman Syndrome | Phase 1 / Phase 2 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 71 | 2021-12-22 | 2026-11-17 |
| A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome GTX-102 - Angelman Syndrome | Phase 1 / Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 74 | 2020-02-24 | 2026-01-09 |
| A Study in Adults and Adolescents With Angelman Syndrome (STARS) OV101 Regimen 1, OV101 regimen 2, Placebo - Angelman Syndrome | Phase 2 | Completed | Healx AI | 88 | 2016-01-01 | 2025-08-03 |
| An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder EPI-743 - Autism Spectrum Disorder | Phase 2 | Withdrawn | Edison Pharmaceuticals Inc | 2014-10-31 | 2022-01-21 | |
| Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome MINOCYCLINE, PLACEBO (for Minocycline) - Angelman Syndrome | Phase 2 | Completed | Puerta de Hierro University Hospital | 32 | 2014-01-01 | 2015-10-21 |
| A Trial of Levodopa in Angelman Syndrome Levodopa, Placebo Oral Capsule - Angelman Syndrome | Phase 2 / Phase 3 | Completed | Wen-Hann Tan | 67 | 2011-01-01 | 2020-07-15 |
Autism Spectrum Disorder (1) · Autistic Disorder (1) · Mitochondrial Diseases (1) · Rare Diseases (1) · Rett Syndrome (1) · cyclopia sequence (1)
Abnormalities, Multiple (10) · Central Nervous System Diseases (10) · Chromosome Disorders (10) · Congenital Abnormalities (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Imprinting Disorders (10) · Movement Disorders (10) · Nervous System Diseases (10) · Child Development Disorders, Pervasive (1) · Disease Attributes (1) · Genetic Diseases, X-Linked (1) · Heredodegenerative Disorders, Nervous System (1) · Intellectual Disability (1) · Mental Disorders (1)
Levodopa (1) · Minocycline (1) · alpha-tocotrienol quinone (1) · carbidopa, levodopa drug combination (1) · cyclo-L-glycyl-L-2-allylproline (1) · gaboxadol (1)
Ultragenyx Pharmaceutical Inc (2) · Edison Pharmaceuticals Inc (1) · Healx AI (1) · Hoffmann-La Roche (1) · Ionis Pharmaceuticals, Inc. (1) · MavriX Bio, LLC (1) · Neuren Pharmaceuticals Limited (1) · Puerta de Hierro University Hospital (1) · Wen-Hann Tan (1)
United States (7) · Australia (4) · France (4) · Israel (4) · Italy (3) · Spain (3) · United Kingdom (3) · Germany (2) · Argentina (1) · Brazil (1) · Canada (1) · Portugal (1)
Amit Rakhit, MD, MBA (1) · Anne Slavotinek, MD (1) · Carlos A. Bacino, MD (1) · Cary Fu, MD (1) · James Shaw (1) · Logan Wink, M.D (1) · Lynne M. Bird, MD (1) · Steven A. Skinner, MD (1) · Wen-Hann Tan, BMBS (1)